Why Work With Us
Upperton is a specialist pharmaceutical CDMO that can, within days of initial contact, start feasibility studies with only a few milligrams of a client’s drug candidate. We offer our clients a complete development package, across all dry powder dosage forms: powders, capsules, tablets, devices for nasal and pulmonary delivery. With experience of working on a range of dosage forms and the expertise to develop the most challenging molecules. From the beginning, our clients will talk to an expert scientific team, who will manage projects with a science-led approach.
What We Do
Upperton Pharma Solutions is a specialist CDMO providing formulation and dosage form development services to the biotechnology and pharmaceutical industries. We offer our clients a complete development service, from early feasibility studies to process optimisation, scale up and clinical trial (GMP / IMP) manufacturing.
We are able to enhance the performance and delivery of our client’s products by utilising an extensive range of formulation technologies. In particular we are one of the world leaders on expertise and know-how in pharmaceutical spray dryings; probably the most versatile and fastest growing technology in the industry.
We have experience of working with a range of dosage forms and the expertise to develop the most challenging of molecules. Our formulation work is complemented by a comprehensive range of analytical services for product testing and ICH stability studies.
Upperton has an extensive, multinational client-base, ranging from virtual and small start-ups to global pharma companies. We pride ourselves on our client-focused, flexible approach and scientific excellence.
Upperton Limited was founded in 1999 by Dr Richard Johnson. The company began life as a spray drying consultation service. In 2008, Upperton started working with external clients on various small spray drying projects; laying the foundation for Upperton’s R&D department.
The R&D department continued to grow organically, through company reinvestment. The team has now completed over 300 projects, several of which have now been launched as commercial products with many others in advanced stages of clinical development.
In November 2018, Upperton completed a successful MHRA inspection and subsequent grant of our MHRA license. This license allows us to manufacture IMP bulk powder and a range of dry powder dosage forms; supporting clinical trials up to Phase III. This marked a turning point in the company’s history, with transition from a CRO to a CDMO. A science-led approach remains at the heart of our R&D activities, whilst our clinical trial manufacturing capabilities enables us to support our clients all the way into the clinic.